True Ileal Amino Acid Digestibility of Tenebrio Molitor Larvae in Women

April 16, 2024 updated by: Diego Moretti

True Ileal Amino Acid Digestibility of Tenebrio Molitor Larvae Determined by Dual Stable Isotope Tracer Method in Young Women

Dietary protein intake of adequate quality is essential for human health. Traditional animal source foods play a key role in providing high quality protein but are associated with a high burden on the environment. Therefore, viable alternative protein sources are needed to be able to meet human nutritional needs for the rapidly increasing world population, while keeping food production within the planetary boundaries. T. molitor (Yellow Mealworm larvae) is a sustainably produced and commercially available edible insect, which contains a high quantity of protein with a favorable amino acid profile. Protein quality evaluation considers the amino acid composition as well as the ileal digestibility of the food's individual amino acids, to assess if human dietary requirements for essential amino acids can be met by the protein source. The present study will measure the digestibility of essential amino acids from T. molitor with a minimally invasive dual stable isotope tracer method that follows a plateau-fed test meal protocol. T. molitor will be intrinsically labelled with the stable isotope deuterium (2H), which will be given along with a reference amino acid mixture of known digestibility, labelled with the stable isotope carbon-13 (13C). Based on the results from the present study, protein quality of T. molitor as a protein source for human nutrition can be assessed, allowing a direct comparison of this novel protein source to other protein sources, such as meat and legumes.

Study Overview

Study Type

Interventional

Enrollment (Actual)

5

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Zürich, Switzerland, 8092
        • ETH Zurich, Laboratory of Human Nutrition

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Female aged between 18-45 years
  • Normal BMI (18.5 - 25 kg/m2)
  • Body weight < 60 kg
  • Signed informed consent
  • Able to communicate and comprehend English
  • Are open-minded towards consuming insect-based meals

Exclusion Criteria:

  • Anaemic (Hb < 12 g/dL)
  • Inflammation (CRP > 5.0 mg/L)
  • Pregnancy or intention to become pregnant during the study or within 30 days after the discontinuation of the study intervention
  • Lactating up to 6 weeks before the study initiation
  • Chronic digestive, renal and/or metabolic diseases
  • Antibiotics in the last 4 weeks prior to the study and during the study
  • Mineral and vitamin supplementation in the last 2 weeks prior to the study
  • Chronic medication intake (except for oral contraceptives)
  • Daily exercise routine of high intensity
  • Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 4 months
  • Participation in any clinical study within the last 30 days
  • Food allergies, especially hypersensitivity to crustacea, dust mites, sea food, gluten, milk, or eggs
  • History of serious illness or infection within 3 months of the study
  • Cigarette smoking (> 1 cigarette per day)
  • Difficulties with blood or breath sampling
  • Participants who cannot be expected to comply with study protocol (e.g., not available for the full 8.5 hours of the study day or unable to follow fasting period)
  • Inability to understand the information sheet and the informed consent form due to cognitive or language reasons

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 2H intrinsically-labeled T.molitor
1 portion of bread and vegetable soup prepared with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture
Test meal with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture will be divided into 10 portions, which will be given hourly over the course of 7 hours. The first consumption will be the priming meal, comprised of 3 portions and will additionally contain 13C sodium bicarbonate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
True ileal amino acid digestibility
Time Frame: 1st day
True ileal amino acid digestibility of intrinsically 2H labelled mealworm larvae (Tenebrio molitor) will be determined, relative to a simultaneously administered 13C labelled amino acids mixture, by measuring the plasma appearance of 13C and 2H isotopic enrichments of amino acids at plateau
1st day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hemoglobin (Hb)
Time Frame: -14 days
Iron status marker
-14 days
C-Reactive Protein (CRP)
Time Frame: -14 days
inflammation status
-14 days
Appearance of 13CO2 enrichment in breath
Time Frame: 1st day
Rate of amino acid oxidation
1st day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Diego Moretti, Prof. Dr., Swiss Distance University of Applied Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 30, 2023

Primary Completion (Actual)

November 30, 2023

Study Completion (Actual)

April 16, 2024

Study Registration Dates

First Submitted

May 23, 2023

First Submitted That Met QC Criteria

May 23, 2023

First Posted (Actual)

June 1, 2023

Study Record Updates

Last Update Posted (Actual)

April 17, 2024

Last Update Submitted That Met QC Criteria

April 16, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malnutrition; Protein

Clinical Trials on 2H intrinsically-labeled T.molitor with 13-C labeled amino acid mixture

Subscribe